Show simple item record

dc.contributor.authorZuidmeer-Jongejan, Laurian
dc.contributor.authorFernandez-Rivas, Montserrat
dc.contributor.authorPoulsen, Lars K
dc.contributor.authorNeubauer, Angela
dc.contributor.authorAsturias, Juan
dc.contributor.authorBlom, Lars
dc.contributor.authorBoye, Joyce
dc.contributor.authorBindslev-Jensen, Carsten
dc.contributor.authorClausen, Michael
dc.contributor.authorFerrara, Rosa
dc.contributor.authorGarosi, Paula
dc.contributor.authorHuber, Hans
dc.contributor.authorJensen, Bettina M
dc.contributor.authorKoppelman, Stef
dc.contributor.authorKowalski, Marek L
dc.contributor.authorLewandowska-Polak, Anna
dc.contributor.authorLinhart, Birgit
dc.contributor.authorMaillere, Bernard
dc.contributor.authorMari, Adriano
dc.contributor.authorMartinez, Alberto
dc.contributor.authorMills, Clare En
dc.contributor.authorNicoletti, Claudio
dc.contributor.authorOpstelten, Dirk-Jan
dc.contributor.authorPapadopoulos, Nikos G
dc.contributor.authorPortoles, Antonio
dc.contributor.authorRigby, Neil
dc.contributor.authorScala, Enrico
dc.contributor.authorSchnoor, Heidi J
dc.contributor.authorSigursdottir, Sigurveig
dc.contributor.authorStavroulakis, Georg
dc.contributor.authorStolz, Frank
dc.contributor.authorSwoboda, Ines
dc.contributor.authorValenta, Rudolf
dc.contributor.authorvan den Hout, Rob
dc.contributor.authorVersteeg, Serge A
dc.contributor.authorWitten, Marianne
dc.contributor.authorvan Ree, Ronald
dc.date.accessioned2013-09-20T14:26:09Z
dc.date.available2013-09-20T14:26:09Z
dc.date.issued2012-03-09
dc.date.submitted2013-09-20
dc.identifier.citationClin Transl Allergy 2012, 2(1):5en_GB
dc.identifier.issn2045-7022
dc.identifier.pmid22409908
dc.identifier.doi10.1186/2045-7022-2-5
dc.identifier.urihttp://hdl.handle.net/2336/302023
dc.descriptionTo access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.en_GB
dc.description.abstractABSTRACT: The FAST project (Food Allergy Specific Immunotherapy) aims at the development of safe and effective treatment of food allergies, targeting prevalent, persistent and severe allergy to fish and peach. Classical allergen-specific immunotherapy (SIT), using subcutaneous injections with aqueous food extracts may be effective but has proven to be accompanied by too many anaphylactic side-effects. FAST aims to develop a safe alternative by replacing food extracts with hypoallergenic recombinant major allergens as the active ingredients of SIT. Both severe fish and peach allergy are caused by a single major allergen, parvalbumin (Cyp c 1) and lipid transfer protein (Pru p 3), respectively. Two approaches are being evaluated for achieving hypoallergenicity, i.e. site-directed mutagenesis and chemical modification. The most promising hypoallergens will be produced under GMP conditions. After pre-clinical testing (toxicology testing and efficacy in mouse models), SCIT with alum-absorbed hypoallergens will be evaluated in phase I/IIa and IIb randomized double-blind placebo-controlled (DBPC) clinical trials, with the DBPC food challenge as primary read-out. To understand the underlying immune mechanisms in depth serological and cellular immune analyses will be performed, allowing identification of novel biomarkers for monitoring treatment efficacy. FAST aims at improving the quality of life of food allergic patients by providing a safe and effective treatment that will significantly lower their threshold for fish or peach intake, thereby decreasing their anxiety and dependence on rescue medication.
dc.languageENG
dc.language.isoenen
dc.relation.urlhttp://dx.doi.org/10.1186/2045-7022-2-5en_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386014/en_GB
dc.rightsArchived with thanks to Clinical and translational allergyen_GB
dc.titleFAST: Towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies.en
dc.typeArticleen
dc.identifier.journalClinical and translational allergyen_GB
dc.rights.accessOpen Access - Opinn aðganguren
html.description.abstractABSTRACT: The FAST project (Food Allergy Specific Immunotherapy) aims at the development of safe and effective treatment of food allergies, targeting prevalent, persistent and severe allergy to fish and peach. Classical allergen-specific immunotherapy (SIT), using subcutaneous injections with aqueous food extracts may be effective but has proven to be accompanied by too many anaphylactic side-effects. FAST aims to develop a safe alternative by replacing food extracts with hypoallergenic recombinant major allergens as the active ingredients of SIT. Both severe fish and peach allergy are caused by a single major allergen, parvalbumin (Cyp c 1) and lipid transfer protein (Pru p 3), respectively. Two approaches are being evaluated for achieving hypoallergenicity, i.e. site-directed mutagenesis and chemical modification. The most promising hypoallergens will be produced under GMP conditions. After pre-clinical testing (toxicology testing and efficacy in mouse models), SCIT with alum-absorbed hypoallergens will be evaluated in phase I/IIa and IIb randomized double-blind placebo-controlled (DBPC) clinical trials, with the DBPC food challenge as primary read-out. To understand the underlying immune mechanisms in depth serological and cellular immune analyses will be performed, allowing identification of novel biomarkers for monitoring treatment efficacy. FAST aims at improving the quality of life of food allergic patients by providing a safe and effective treatment that will significantly lower their threshold for fish or peach intake, thereby decreasing their anxiety and dependence on rescue medication.


This item appears in the following Collection(s)

Show simple item record